This observational study aims to investigate a clinical cohort of patients with locally advanced esophageal cancer undergoing neoadjuvant chemoimmunotherapy. By integrating multimodal clinical data-including demographic characteristics, medical history, imaging studies, pathological findings, and laboratory tests-and employing deep learning algorithms, the study seeks to develop predictive models for the early and accurate assessment of treatment response prior to surgery. Specifically, this study focuses on addressing the following key scientific questions:
1. Can multimodal clinical data be used to construct an accurate model for predicting pathological complete response (pCR) following neoadjuvant therapy? 2. Can deep learning models enable early identification of patients with suboptimal response to neoadjuvant therapy, defined as stable disease (SD) or progressive disease (PD), before surgery?
Patients with histologically confirmed esophageal cancer based on biopsy results;
Patients recommended for neoadjuvant chemoimmunotherapy following multidisciplinary team (MDT) discussion or evaluation by thoracic surgery specialists;
Patients who received neoadjuvant chemoimmunotherapy;
Patients with complete imaging data before and after neoadjuvant treatment.
Patients deemed eligible for surgery by the thoracic surgery team but who refused surgical treatment;
Patients with missing or poor-quality CT images;
Patients with concurrent malignancies other than esophageal cancer;
Patients with incomplete clinical data.
Patients with esophageal cancer who received neoadjuvant therapy at the Second Xiangya Hospital of Central South University
Cohort
Retrospective
Not listed
pCR
Pathologic Complete Response
Non-Favorable Responses
stable disease/progressive disease
Click on the lead sponsor to view all of their trials.
